Director Dealing and Issue of Equity

Plethora Solutions Holdings PLC

("Plethora" or the "Company")

Director Dealing and Issue of Equity

Plethora Solutions Holdings plc (AIM: PLE) announces that under the terms of the convertible loan notes issued on 18 March 2013 ("Loan Notes"), it has received notice from Maven Capital Partners (UK) LLP ("Maven"), as a manager of the Capital for Enterprise Fund A LP ("CfE"), Jim Mellon and Galloway Limited^  ("Galloway") to convert their convertible loan notes into ordinary shares of 1p each ("Ordinary Shares") ("Conversion") as detailed below at a price of 2p per share.

^Galloway Limited is a company which is indirectly wholly owned by the trustee of a settlement under which James Mellon has a life interest.

*Includes the Galloway Loan Notes with a nominal value of £850,000

Following the Conversion, Jim Mellon (Chairman to the Company) and Maven are now interested in 246,613,861 and 67,556,516 Ordinary Shares representing a beneficial interest of 29.95% (including the interest held by Regent Pacific Group Limited) and 8.21% in the share capital of the Company respectively. Jim Mellon has agreed with the Company to defer £340,000 of his entitlement under the Loan Notes into a new convertible loan note that will accrue a yield of 5% per annum payable quarterly in arrears in cash and to be repaid on 31 March 2020. Upon redemption the loan may, at the option of the bearer, be converted into new Ordinary Shares at a price of 2p per share. All security granted under the Loan Notes will be released by Maven, Jim Mellon and Galloway.

Application has been made for the new Ordinary Shares issued on conversion of the loan notes to be admitted to trading on AIM ("Admission") and it is expected that Admission will take place on 8 April 2014.

Following the issue and allotment of 142,285,957 Ordinary Shares connected with today's conversion of loan notes, the nominal value of the outstanding convertible debt issued by the Company will fall to £340,000.00 from £1,969,595.

Following Admission, the Company will have 823,297,686 Ordinary Shares in issue. This figure may be used by shareholders in Plethora as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

About PSD502™ & Premature Ejaculation:

PSD502™ is a topical spray for the treatment of premature ejaculation containing lidocaine and prilocaine in a eutectic-like mixture. In two large, double blind, pivotal Phase III studies PSD502™ showed a highly significant and clinically meaningful effect increasing mean intravaginal ejaculatory latency time at baseline from 0.5 minutes to 3.2 minutes at week 12. 87% of the patients in the studies were considered as responders with the product being well tolerated with no significant safety issues. PSD502™ also showed positive effects across a wide range of other parameters including partner satisfaction. PSD502™ was approved by the European Commission in November 2013.

Premature ejaculation is possibly the most common form of sexual dysfunction in men. Epidemiological studies conducted in the US and in Europe indicate a prevalence of 20% to 30% in men of all ages. There is currently no globally approved and effective pharmaceutical treatment for this condition.

The premature ejaculation market offers significant potential for development and growth given the absence of any widely approved pharmaceutical therapy with good patient acceptance. As a result an effective drug therapy for premature ejaculation may have a commercial potential comparable to erectile dysfunction drugs.

About Plethora

Plethora is headquartered in the UK and is listed on the London Stock Exchange (AIM: PLE LN). Further information is available at www.plethorasolutions.co.uk 

Plethora is focused on commercializing PSD502™ for the treatment of premature ejaculation with strategic marketing partners and obtaining NDA approval for PSD502™ with the FDA.